BBVA USA’s GSK GSK Stock Holding History

BBVA USA’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$14K	Hold	294	–	–	﹤0.01%	798
2021 Q2	$15K	Buy	+294	New	+$14.1K	﹤0.01%	823

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBVA USA's GSK Position: Q3 2021 in Review

BBVA USA held its GSK (GSK) position steady in Q3 2021 at 294 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

BBVA USA first reported a position in GSK in Q2 2021 and has held it in 2 quarters since. The position peaked at $15K in Q2 2021. 792 funds tracked by Wall St. Rank hold GSK as of Q3 2021.

BBVA USA held 294 shares of GSK worth $14K as of Q3 2021.
BBVA USA left its GSK share count unchanged in Q3 2021.
GSK made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #798 holding.
BBVA USA first reported a position in GSK in Q2 2021 and has held it in 2 quarters since.
BBVA USA's GSK position peaked at $15K in Q2 2021.
792 funds tracked by Wall St. Rank held GSK as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.